Market Outlook

Ulcerative colitis (UC) is a chronic intermittent relapsing disorder of the large intestine and rectum, characterized by diarrhea, abdominal pain, rectal bleeding, fever, and weight loss. The primary goal of UC treatment is to induce and maintain remission. Treatment of UC patients typically begins with conventional agents (e.g., 5-ASAs), which are often effective for those with more mild to moderate disease, but progresses to more-potent drugs, such as immunosuppressants and/or biologics, as needed. Among the biologics, TNF-alpha inhibitors (e.g., Janssen/Merck’s Remicade, AbbVie/Eisai’s Humira) and CAM inhibitors (e.g., Takeda’s Entyvio) are the mainstays of treatment. However, therapies such as Pfizer’s Xeljanz (the first approved oral Jak inhibitor) and Janssen’s Stelara (approved for CD, preregistered for UC) have a small—but growing—market share.

Questions Answered

  • What patient share do key therapies and brands garner by line of therapy in newly diagnosed UC patients?
  • What are the quarterly trends in prescribing among recently treated and new diagnosed adult UC patients?
  • How have Remicade and Humira been integrated into the treatment algorithm and what is its source of business?
  • What proportion of adult UC patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of adult UC patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients with UC?

Product Description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, so you can accurately assess your source of business, benchmark usage against competitors, and quantify areas of opportunity for your marketed or emerging brand.

Table of contents

  • Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US) - Adult
    • Treatment Algorithm: Claims Data Analysis-Ulcerative Colitis Adult-US PPT [January 2019]

Author(s): Ajay Puri, MBA

Ajay Puri is a Research Associate on the Immune and Inflammatory team at Decision Resources Group. He currently focuses on Inflammatory bowel disease (IBD). He holds a bachelor’s degree in Pharmacy and has earned his MBA in Pharmaceutical marketing from NIPER, Mohali. Prior to joining DRG, Ajay worked as a Business Research Associate (Oncology) at ZS Associates. He has worked on multiple client projects revolving around competitive intelligence, opportunity assessment, trend analysis, clinical trial analysis, and product/company profiling.  


Related Reports

Ulcerative Colitis | Current Treatment | Detailed, Expanded Analysis (EU5)

Multiple well-established therapies are currently available to treat ulcerative colitis (UC) in Europe. TNF-&alp...

View Details

Ulcerative Colitis | Landscape & Forecast | Disease Landscape & Forecast

MARKET OUTLOOK We expect the ulcerative colitis (UC) therapy market to grow steadily over the next decade. The anticipated entry of first-in-

View Details

Ulcerative Colitis | Access & Reimbursement | Detailed, Expanded Analysis (US)

TNF-α inhibitors are well entrenched in the U.S. ulcerative colitis (UC) and Crohn’s disease (

View Details

Ulcerative Colitis | Emerging Therapies | Xeljanz (Ulcerative Colitis) Launch Tracking Wave 3

Pfizer’s Xeljanz is the first-in-class Jak inhibitor approved for ulcerative colitis (UC) in the United S...

View Details